88927496
May 21, 2020
medical diagnostic kits consisting primarily of medical diagnostic reagents for detection or quantitative analysis of BK virus infection or reactivation; medical diagnostic kits consisting primarily of medical diagnostic reagents for detection or quantitative analysis of kidney transplant rejection; medical diagnostic kits consisting primarily of medical diagnostic reagents for detection or quantitative analysis of Epstein-Barr virus infection; medical diagnostic kits consisting primarily of medical diagnostic reagents for detection or quantitative analysis of Cytomegalo virus infection; medical diagnostic kits consisting primarily of medical diagnostic reagents for prediction of targeted therapy efficacy for metastatic colorectal cancer; medical diagnostic kits consisting primarily of medical diagnostic reagents for prediction of targeted therapy efficacy for non-small cell lung cancer; medical diagnostic kits consisting primarily of medical diagnostic reagents for prognosis of liver cancer after liver transplant; medical diagnostic kits consisting primarily of medical diagnostic reagents for detection or quantitative analysis of liver cancer; medical diagnostic kits consisting primarily of medical diagnostic reagents for detection or quantitative analysis of pancreatic cancer; medical diagnostic kits consisting primarily of medical diagnostic reagents for detection or quantitative analysis of lung cancer; medical diagnostic kits consisting primarily of medical diagnostic reagents for detection or quantitative analysis of corona virus infection or reactivation; medical diagnostic kits consisting primarily of medical diagnostic reagents for detection or quantitative analysis of COVID-19 virus infection or reactivation
Pharmaceuticals